AcademicLabs

How much does timing matter in drug development? Does being first, second, or fifth into a therapeutic space really change your company’s fortunes? And what can past examples tell us about smarter portfolio decisions today?

Join pharma strategist **Mark Tillotson** as he unpacks:

*   The relationship between order of entry into R\&D programs and long-term company value.
*   Case studies where herding paid off - and where it destroyed value.
*   Practical implications for how pharma and biotech should approach pipeline and portfolio choices.

Mark will share a fresh analysis powered by recent data - made feasible by AcademicLabs.com - to explore how companies can avoid the risks of herd behavior and redirect resources to higher-impact opportunities.

At the end, you’ll also get a quick look at how you can try the platform and the AI yourself with a complimentary two-week trial.
